Oryzon Genomics S.A. (ORYZF)

Market Cap	272.62M +14.3%
Revenue (ttm)	12.61M +58.5%
Net Income	-2.58M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	3.700
Previous Close	3.650
Day's Range	3.700 - 3.700
52-Week Range	3.030 - 4.375
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 28, 2026

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORYZF

Financial Performance

In 2025, Oryzon Genomics's revenue was $12.84 million, an increase of 68.51% compared to the previous year's $7.62 million. Losses were -$3.06 million, -17.41% less than in 2024.